Drug
Vactosertib clinical trials
Also written TEW-7197 and EW7197.
- studies test it
- 19
- open now
- 2
- in phase 3
- 0
- first study started
- 2014
Keep track of what changes. Save the vactosertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 13
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 9
MedPacto, Inc. (10) · Samsung Medical Center (2) · Koen van Besien (1) · Melissa Lumish (1) · David Wald (1) · Weill Medical College of Cornell University (1) · Yonsei University (1) · Hark Kyun Kim (1)
Often tested with
Tested in the same studies.
Pomalidomide (1) · Interleukin-2 (1) · Pembrolizumab (1) · Durvalumab (1)
Studies
Open first, then newest update. How each study uses vactosertib is read from its arms, and is right about nine times in ten.
Testing it · 19
- Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive OsteosarcomaRecruitingPhase 1/2MedPacto, Inc.NCT05588648Written as Vactosertib
- Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal AdenocarcinomaRecruitingPhase 2Melissa LumishNCT06044311Written as Vactosertib
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedPhase 1David WaldNCT05400122Written as Vactosertib
- Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN PatientsTerminatedPhase 2Weill Medical College of Cornell UniversityNCT04103645Written as Vactosertib
- Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLCCompletedPhase 1/2MedPacto, Inc.NCT03732274Written as TEW-7197
- Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point InhibitorTerminatedPhase 2Yonsei UniversityNCT05436990Written as Pembrolizumab, Vactosertib
- Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric CancerCompletedPhase 1/2MedPacto, Inc.NCT03724851Written as TEW-7197
- TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric CancerCompletedPhase 1/2MedPacto, Inc.NCT03698825Written as TEW-7197
- Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) SubjectsTerminatedPhase 2MedPacto, Inc.NCT04515979Written as Vactosertib 300 mg BID and pembrolizumab 200 mg IV
- Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionWithdrawnPhase 2MedPacto, Inc.NCT04064190Written as Vactosertib(TEW-7197)/ Durvalumab
- Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)WithdrawnPhase 2MedPacto, Inc.NCT06219733Written as Vactosertib
- Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple MyelomaCompletedPhase 1Koen van BesienNCT03143985Written as Vactosertib
- Vactosertib and Durvalumab in Gastric CancerStatus unknownPhase 2Hark Kyun KimNCT04893252Written as durvalumab and vactosertib
- Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.Status unknownPhase 1Samsung Medical CenterNCT04258072Written as Vactosertib
- As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to BiomarkersStatus unknownPhase 2Samsung Medical CenterNCT04656002Written as Vactosertib
- Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-PaclitaxelStatus unknownPhase 1/2Joon Oh ParkNCT03666832Written as TEW-7197
- Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDSCompletedPhase 1MedPacto, Inc.NCT03074006Written as TEW-7197
- Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy SubjectsCompletedPhase 1MedPacto, Inc.NCT03704675Written as TEW-7197
- First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid TumorsCompletedPhase 1MedPacto, Inc.NCT02160106Written as TEW-7197
Given in every arm · 1 — vactosertib is usual care beside what is tested
Codes
What other systems call vactosertib · ClinicalTrials.gg INT000042
- MeSH (NLM) C000590371vactosertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6T4O391P5YVACTOSERTIBConfirmed FDA, NLM
- NCI Thesaurus C116357VactosertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000590371 | vactosertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6T4O391P5Y | VACTOSERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C116357 | Vactosertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.